ev3 Inc.

ev3 Inc. reported revenue results for the first quarter of 2008. For the quarter,the company reported preliminary revenue of approximately $101.3 million. The company indicated that overall revenue growth of approximately 10% compared to the fourth quarter of 2007 was driven by consistent growth across all of its major product groups including its pre-merger peripheral vascular business segment,the atherectomy product line acquired from FoxHollow and the neurovascular business segment. The company attributed most of the shortfall to expectations to a slower than anticipated rebound in U.S. atherectomy following the integration of the ev3 and FoxHollow sales organizations.